These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1560366)

  • 1. LY215840, a potent 5-hydroxytryptamine (5-HT)2 receptor antagonist, blocks vascular and platelet 5-HT2 receptors and delays occlusion in a rabbit model of thrombosis.
    Cohen ML; Robertson DW; Bloomquist WE; Wilson HC
    J Pharmacol Exp Ther; 1992 Apr; 261(1):202-8. PubMed ID: 1560366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LY215840, a high-affinity 5-HT7 receptor ligand, blocks serotonin-induced relaxation in canine coronary artery.
    Cushing DJ; Zgombick JM; Nelson DL; Cohen ML
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1560-6. PubMed ID: 8667223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Hydroxytryptamine2 receptor antagonist activity of the acid metabolite (1-isopropyl dihydrolysergic acid) of the ergoline ester, sergolexole (LY281067).
    Cohen ML; Parli CJ; Fuller RW
    J Pharmacol Exp Ther; 1989 Dec; 251(3):1006-11. PubMed ID: 2600800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular serotonin 5-hydroxytryptamine2 receptor blockade by LY215840: lack of effect upon neointima formation in balloon-injured rat carotid arteries.
    Kauffman RF; Bean JS; Bloomquist WE; Cohen ML
    J Pharmacol Exp Ther; 1993 Jul; 266(1):450-5. PubMed ID: 8331571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonin-induced contraction in porcine coronary artery: use of ergolines to support vascular 5-hydroxytryptamine2-receptor heterogeneity.
    Cushing DJ; Cohen ML
    J Pharmacol Exp Ther; 1993 Jan; 264(1):193-200. PubMed ID: 8423526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical pharmacology of a new serotonergic receptor antagonist, LY281067.
    Cohen ML; Fuller RW; Kurz KD; Parli CJ; Mason NR; Meyers DB; Smallwood JK; Toomey RE
    J Pharmacol Exp Ther; 1988 Jan; 244(1):106-12. PubMed ID: 3335993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LY53857, a selective and potent serotonergic (5-HT2) receptor antagonist, does not lower blood pressure in the spontaneously hypertensive rat.
    Cohen ML; Fuller RW; Kurz KD
    J Pharmacol Exp Ther; 1983 Nov; 227(2):327-32. PubMed ID: 6313898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LY53857, a 5HT2 receptor antagonist, delays occlusion and inhibits platelet aggregation in a rabbit model of carotid artery occlusion.
    Wilson HC; Coffman W; Killam AL; Cohen ML
    Thromb Haemost; 1991 Sep; 66(3):355-60. PubMed ID: 1746008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic activity of SR 46349, a novel, potent and selective 5-HT2 receptor antagonist.
    Herbert JM; Bernat A; Barthelemy G; Dol F; Rinaldi M
    Thromb Haemost; 1993 Mar; 69(3):262-7. PubMed ID: 8470049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies with new ergoline derivatives on the effects of central and peripheral 5-hydroxytryptamine receptors.
    Harhammer R; Schäfer U; Ott T
    Arzneimittelforschung; 1992 Oct; 42(10):1175-9. PubMed ID: 1472137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the serotonin receptors that mediate smooth muscle contraction in canine and porcine coronary artery.
    Cushing DJ; Cohen ML
    J Pharmacol Exp Ther; 1992 Jun; 261(3):856-62. PubMed ID: 1602389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-HT2-receptor antagonists: alpha 1- vs. 5-HT2-receptor blocking properties in blood vessels.
    Cohen ML; Schenck KW; Kurz KD
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S25-9. PubMed ID: 2459510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology.
    Adams JW; Ramirez J; Shi Y; Thomsen W; Frazer J; Morgan M; Edwards JE; Chen W; Teegarden BR; Xiong Y; Al-Shamma H; Behan DP; Connolly DT
    J Pharmacol Exp Ther; 2009 Oct; 331(1):96-103. PubMed ID: 19628629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic treatment of hydroxytryptamine type 2a receptor antagonist sarpogrelate hydrochloride modulates the vasoreactivity of serotonin in experimental rabbit vein grafts.
    Kodama A; Komori K; Kajikuri J; Itoh T
    J Vasc Surg; 2009 Sep; 50(3):617-25. PubMed ID: 19700096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological profile of a new potent 5-hydroxytryptamine (5-HT2) alpha 1-receptor antagonist.
    Schröder G; Beckmann R; Gerbling KP; Loge O; Maass B; Müller B; Seidelmann D; Schneider HH; Schulz BG; Stürzebecher CS
    Arzneimittelforschung; 1988 Jun; 38(6):765-70. PubMed ID: 2902861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B/5-HT2A receptor antagonist.
    Berry CN; Lorrain J; Lochot S; Delahaye M; Lalé A; Savi P; Lechaire I; Ferrari P; Bernat A; Schaeffer P; Janiak P; Duval N; Grosset A; Herbert JM; O'Connor SE
    Thromb Haemost; 2001 Mar; 85(3):521-8. PubMed ID: 11307825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between receptors mediating serotonin (5-HT) contractions in the canine basilar artery to 5-HT1, 5-HT2 and rat stomach fundus 5-HT receptors.
    Cohen ML; Colbert WE
    J Pharmacol Exp Ther; 1986 Jun; 237(3):713-8. PubMed ID: 3712277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of serotonin-amplified human platelet aggregation by ketanserin, ritanserin, and the ergoline 5HT2 receptor antagonists-LY53857, sergolexole, and LY237733.
    McBride PA; Mann JJ; Nimchinsky E; Cohen ML
    Life Sci; 1990; 47(23):2089-95. PubMed ID: 2125095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical studies on LY237733, a potent and selective serotonergic antagonist.
    Foreman MM; Fuller RW; Nelson DL; Calligaro DO; Kurz KD; Misner JW; Garbrecht WL; Parli CJ
    J Pharmacol Exp Ther; 1992 Jan; 260(1):51-7. PubMed ID: 1731051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological activity of the isomers of LY53857, potent and selective 5-HT2 receptor antagonists.
    Cohen ML; Kurz KD; Mason NR; Fuller RW; Marzoni GP; Garbrecht WL
    J Pharmacol Exp Ther; 1985 Nov; 235(2):319-23. PubMed ID: 4057073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.